Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Ranking) – Expense analysts at Jefferies Economic Group boosted their Q2 2022 earnings for every share estimates for Nautilus Biotechnology in a study report issued to clientele and buyers on Wednesday, May well 4th. Jefferies Financial Group analyst B. Couillard now forecasts that the corporation will article earnings for each share of ($.15) for the quarter, up from their prior forecast of ($.16). Jefferies Financial Group also issued estimates for Nautilus Biotechnology’s Q3 2022 earnings at ($.16) EPS, Q4 2022 earnings at ($.18) EPS, FY2022 earnings at ($.62) EPS, Q1 2023 earnings at ($.18) EPS and FY2023 earnings at ($.72) EPS.
Other analysts also recently issued investigate stories about the enterprise. Zacks Financial commitment Research downgraded Nautilus Biotechnology from a “hold” ranking to a “sell” score in a study notice on Saturday, April 23rd. The Goldman Sachs Team dropped their value objective on Nautilus Biotechnology from $9.00 to $5.00 and set a “neutral” rating on the stock in a study notice on Wednesday, April 13th. A person equities study analyst has rated the inventory with a provide score, two have assigned a keep rating and two have assigned a get rating to the company’s inventory. In accordance to info from MarketBeat, the inventory currently has an average ranking of “Hold” and a consensus target rate of $8.67.
Shares of Nautilus Biotechnology stock opened at $4.21 on Monday. The business has a market capitalization of $523.99 million and a PE ratio of -7.39. Nautilus Biotechnology has a 12 month low of $3.36 and a 12 month high of $12.38. The stock’s fifty day basic transferring normal is $4.14 and its 200 working day simple moving common is $4.55.
Nautilus Biotechnology (NASDAQ:NAUT – Get Score) very last issued its quarterly earnings information on Thursday, February 24th. The enterprise described ($.13) EPS for the quarter, topping the consensus estimate of ($.15) by $.02.
A quantity of institutional investors have recently bought and offered shares of NAUT. Sentinel Believe in Co. LBA obtained a new stake in shares of Nautilus Biotechnology in the very first quarter valued at roughly $369,000. Sciencast Management LP obtained a new situation in Nautilus Biotechnology throughout the initially quarter valued at roughly $283,000. FNY Investment decision Advisers LLC grew its stake in shares of Nautilus Biotechnology by 151.1% for the duration of the first quarter. FNY Expenditure Advisers LLC now owns 31,640 shares of the company’s inventory worthy of $137,000 after getting an supplemental 19,040 shares for the duration of the past quarter. CAPROCK Group Inc. purchased a new stake in shares of Nautilus Biotechnology during the first quarter worthy of $108,000. Lastly, BlackRock Inc. grew its stake in shares of Nautilus Biotechnology by 1.9% throughout the fourth quarter. BlackRock Inc. now owns 1,251,848 shares of the company’s inventory truly worth $6,485,000 immediately after buying an extra 23,560 shares during the previous quarter. Institutional traders and hedge cash very own 47.89% of the company’s stock.
In associated information, CEO Sujal M. Patel acquired 50,000 shares of the firm’s inventory in a transaction dated Thursday, March 3rd. The inventory was acquired at an average price tag of $3.60 for each share, for a whole transaction of $180,000.00. The acquisition was disclosed in a doc submitted with the SEC, which is offered by way of this backlink.
Nautilus Biotechnology Enterprise Profile (Get Rating)
Nautilus Biotechnology, Inc, a advancement stage existence sciences business, engages in creating a platform engineering for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics system that includes end-to-conclusion alternative comprised of instruments, consumables, and software assessment.
Even further Reading
Get News & Rankings for Nautilus Biotechnology Day by day – Enter your email handle under to obtain a concise everyday summary of the latest information and analysts’ rankings for Nautilus Biotechnology and linked businesses with MarketBeat.com’s Absolutely free day by day e-mail e-newsletter.